Literature DB >> 23468073

NF-κB signaling and bone resorption.

Y Abu-Amer1.   

Abstract

The transcription factor NF-κB is a family of proteins involved in signaling pathways essential for normal cellular functions and development. Deletion of various components of this pathway resulted with abnormal skeletal development. Research in the last decade has established that NF-κB signaling mediates RANK ligand-induced osteoclastogenesis. Consistently, it was shown that inhibition of NF-κB was an effective approach to inhibit osteoclast formation and bone resorptive activity. Identification of the molecular machinery underlying NF-κB activation permitted osteoclast-specific deletion of the major components of this pathway. As a result, it was clear that deletion of members of the proximal IKK kinase complex and the distal NF-κB subunits and downstream regulators affected skeletal development. These studies provided several targets of therapeutic intervention in osteolytic diseases. NF-κB activity has been also described as the centerpiece of inflammatory responses and is considered a potent mediator of inflammatory osteolysis. Indeed, inflammatory insults exacerbate physiologic RANKL-induced NF-κB signals leading to exaggerated responses and to inflammatory osteolysis. These superimposed NF-κB activities appear to underlie several bone pathologies. This review will describe the individual roles of NF-κB molecules in bone resorption and inflammatory osteolysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468073      PMCID: PMC3884829          DOI: 10.1007/s00198-013-2313-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  129 in total

1.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.

Authors:  B R Wong; D Besser; N Kim; J R Arron; M Vologodskaia; H Hanafusa; Y Choi
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

2.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

Review 4.  NF-kappaB activation: the I kappaB kinase revealed?

Authors:  I Stancovski; D Baltimore
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

Review 5.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

6.  A novel NEMO gene mutation causing osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and immunodeficiency (OL-HED-ID).

Authors:  Catherine M L Roberts; Janet E Angus; Ian H Leach; Elizabeth M McDermott; David A Walker; Jane C Ravenscroft
Journal:  Eur J Pediatr       Date:  2010-05-21       Impact factor: 3.183

Review 7.  Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

Authors:  T Pincus; Y Yazici; T Sokka; D Aletaha; J S Smolen
Journal:  Clin Exp Rheumatol       Date:  2003 Sep-Oct       Impact factor: 4.473

8.  The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis.

Authors:  Hidefumi Fukushima; Akihiro Nakao; Fujio Okamoto; Masashi Shin; Hiroshi Kajiya; Seiji Sakano; Anna Bigas; Eijiro Jimi; Koji Okabe
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

Review 9.  Osteoporosis and inflammation.

Authors:  Gregory R Mundy
Journal:  Nutr Rev       Date:  2007-12       Impact factor: 7.110

Review 10.  Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies.

Authors:  Yousef Abu-Amer; Isra Darwech; John C Clohisy
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  91 in total

1.  A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and inflammatory bone destruction.

Authors:  Yanhui Tan; Wende Deng; Yueyang Zhang; Minhong Ke; Binhua Zou; Xiaowei Luo; Jianbin Su; Yiyuan Wang; Jialan Xu; Kutty Selva Nandakumar; Yonghong Liu; Xuefeng Zhou; Xiaojuan Li
Journal:  Br J Pharmacol       Date:  2020-08-11       Impact factor: 8.739

2.  Osseous Dysplasia with Gross Jaw Expansion: A Review of 18 Lesions.

Authors:  Erich J Raubenheimer; Claudia E Noffke; Sonja C Boy
Journal:  Head Neck Pathol       Date:  2016-05-09

3.  NF-κB/let-7f-5p/IL-10 pathway involves in wear particle-induced osteolysis by inducing M1 macrophage polarization.

Authors:  Xu-Ren Gao; Jian Ge; Wei-Yi Li; Wang-Chen Zhou; Lei Xu; De-Qin Geng
Journal:  Cell Cycle       Date:  2018-09-19       Impact factor: 4.534

4.  Serum Albumin and Future Risk of Hip, Humeral, and Wrist Fractures in Caucasian Men: New Findings from a Prospective Cohort Study.

Authors:  Setor K Kunutsor; Ari Voutilainen; Michael R Whitehouse; Samuel Seidu; Jussi Kauhanen; Ashley W Blom; Jari A Laukkanen
Journal:  Med Princ Pract       Date:  2019-03-21       Impact factor: 1.927

5.  METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-κB signaling pathway.

Authors:  Jian Huang; Yi-Hsiang Hsu; Maxrco Brotto; David Karasik; Chenglin Mo; Eduardo Abreu; Douglas P Kiel; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

Review 6.  NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases.

Authors:  T-H Lin; J Pajarinen; L Lu; A Nabeshima; L A Cordova; Z Yao; S B Goodman
Journal:  Adv Protein Chem Struct Biol       Date:  2016-12-09       Impact factor: 3.507

Review 7.  Recent developments in metabolic bone diseases: a gnathic perspective.

Authors:  Erich J Raubenheimer; Claudia E Noffke; Hilde D Hendrik
Journal:  Head Neck Pathol       Date:  2014-11-20

8.  A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.

Authors:  Muna S Elburki; Carlos Rossa; Morgana R Guimarães-Stabili; Hsi-Ming Lee; Fabiana A Curylofo-Zotti; Francis Johnson; Lorne M Golub
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

9.  The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.

Authors:  Kakeru Ozaki; Takanori Yamada; Tetsuhiro Horie; Atsushi Ishizaki; Manami Hiraiwa; Takashi Iezaki; Gyujin Park; Kazuya Fukasawa; Hikari Kamada; Kazuya Tokumura; Mei Motono; Katsuyuki Kaneda; Kazuma Ogawa; Hiroki Ochi; Shingo Sato; Yasuhiro Kobayashi; Yun-Bo Shi; Peter M Taylor; Eiichi Hinoi
Journal:  Sci Signal       Date:  2019-07-09       Impact factor: 8.192

10.  NF-κB decoy oligodeoxynucleotide inhibits wear particle-induced inflammation in a murine calvarial model.

Authors:  Taishi Sato; Jukka Pajarinen; Tzu-hua Lin; Yasunobu Tamaki; Florence Loi; Kensuke Egashira; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2015-07-14       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.